Janssen submits EMA filing for bladder cancer treatment
Drug Discovery World
SEPTEMBER 14, 2023
8 On August 29, Janssen submitted a supplemental New Drug Application (sNDA) to the FDA seeking full approval of erdafitinib in this indication based on Cohort 1 of the Phase III THOR study. Prognostic value and clinical significance of FGFR genomic alterations (GAs) in metastatic urothelial cancer patients. J Clin Med.
Let's personalize your content